Ubs Group Ag Cerus Corp Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Cerus Corp stock. As of the latest transaction made, Ubs Group Ag holds 285,170 shares of CERS stock, worth $402,089. This represents 0.0% of its overall portfolio holdings.

Number of Shares

285,170

Previous 1,309,002 78.21%

Holding current value

$402,089

Previous $2.02 Million 80.35%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$1.39 - $2.15 $1.42 Million - $2.2 Million	-1,023,832 Reduced 78.21%	285,170 $396,000
Q4 2024 Feb 14, 2025	BUY	$1.52 - $2.03 $1.62 Million - $2.17 Million	1,066,666 Added 440.16%	1,309,002 $2.02 Million
Q3 2024 Nov 14, 2024	BUY	$1.7 - $2.39 $20,226 - $28,436	11,898 Added 5.16%	242,336 $421,000
Q2 2024 Aug 13, 2024	SELL	$1.62 - $2.04 $192,083 - $241,882	-118,570 Reduced 33.97%	230,438 $405,000
Q1 2024 May 13, 2024	SELL	$1.66 - $2.42 $95,410 - $139,091	-57,476 Reduced 14.14%	349,008 $659,000
Q4 2023 Feb 09, 2024	BUY	$1.25 - $2.35 $125,170 - $235,319	100,136 Added 32.69%	406,484 $878,000
Q3 2023 Nov 09, 2023	SELL	$1.5 - $3.07 $28,575 - $58,483	-19,050 Reduced 5.85%	306,348 $496,000
Q2 2023 Aug 11, 2023	BUY	$1.79 - $2.9 $222,985 - $361,261	124,573 Added 62.03%	325,398 $800,000
Q1 2023 May 12, 2023	SELL	$2.65 - $3.81 $1.36 Million - $1.95 Million	-512,124 Reduced 71.83%	200,825 $596,000
Q4 2022 Feb 08, 2023	BUY	$3.38 - $4.22 $153,844 - $192,077	45,516 Added 6.82%	712,949 $2.6 Million
Q3 2022 Nov 10, 2022	SELL	$3.43 - $5.83 $2,723 - $4,629	-794 Reduced 0.12%	667,433 $2.4 Million
Q2 2022 Aug 10, 2022	SELL	$4.41 - $5.69 $44,188 - $57,013	-10,020 Reduced 1.48%	668,227 $3.54 Million
Q1 2022 May 16, 2022	SELL	$4.81 - $6.99 $115,141 - $167,326	-23,938 Reduced 3.41%	678,247 $3.72 Million
Q4 2021 Feb 14, 2022	BUY	$5.97 - $7.93 $520,195 - $690,980	87,135 Added 14.17%	702,185 $4.78 Million
Q3 2021 Nov 15, 2021	BUY	$4.79 - $6.68 $2.75 Million - $3.83 Million	573,420 Added 1377.42%	615,050 $3.75 Million
Q2 2021 Aug 13, 2021	SELL	$5.35 - $6.35 $1.02 Million - $1.21 Million	-190,303 Reduced 82.05%	41,630 $246,000
Q1 2021 May 12, 2021	BUY	$5.68 - $7.87 $369,211 - $511,565	65,002 Added 38.94%	231,933 $1.39 Million
Q4 2020 Feb 11, 2021	SELL	$5.25 - $8.56 $1.49 Million - $2.43 Million	-284,027 Reduced 62.98%	166,931 $1.16 Million
Q3 2020 Nov 12, 2020	BUY	$5.78 - $7.47 $146,216 - $188,968	25,297 Added 5.94%	450,958 $2.82 Million
Q2 2020 Jul 31, 2020	BUY	$4.5 - $7.02 $1.34 Million - $2.09 Million	297,575 Added 232.32%	425,661 $2.81 Million
Q1 2020 May 01, 2020	BUY	$2.87 - $5.49 $239,619 - $458,365	83,491 Added 187.22%	128,086 $596,000
Q4 2019 Feb 14, 2020	SELL	$3.84 - $4.86 $36,433 - $46,111	-9,488 Reduced 17.54%	44,595 $188,000
Q3 2019 Nov 14, 2019	BUY	$4.86 - $6.05 $106,511 - $132,591	21,916 Added 68.13%	54,083 $279,000
Q2 2019 Aug 14, 2019	SELL	$4.51 - $6.6 $89,090 - $130,376	-19,754 Reduced 38.05%	32,167 $181,000
Q1 2019 May 14, 2019	SELL	$5.16 - $6.85 $127,596 - $169,386	-24,728 Reduced 32.26%	51,921 $323,000
Q4 2018 Feb 14, 2019	BUY	$4.89 - $7.16 $144,665 - $211,821	29,584 Added 62.86%	76,649 $389,000
Q3 2018 Nov 14, 2018	SELL	$6.89 - $7.78 $121,642 - $137,355	-17,655 Reduced 27.28%	47,065 $339,000
Q2 2018 Aug 14, 2018	BUY	$5.19 - $7.25 $49,445 - $69,070	9,527 Added 17.26%	64,720 $432,000
Q1 2018 May 15, 2018	BUY	$3.56 - $5.74 $1,776 - $2,864	499 Added 0.91%	55,193 $302,000
Q4 2017 Feb 14, 2018	SELL	$2.76 - $3.95 $57,391 - $82,136	-20,794 Reduced 27.55%	54,694 $185,000
Q3 2017 Nov 14, 2017	BUY	$2.22 - $2.73 $44,883 - $55,195	20,218 Added 36.58%	75,488 $206,000
Q2 2017 Aug 14, 2017	BUY	N/A	157 Added 0.28%	55,270 $139,000
Q1 2017 Nov 14, 2017	BUY	N/A	55,113	55,113 $246,000

Others Institutions Holding CERS

# of Institutions

167

Shares Held

149M

Call Options Held

24.2K

Put Options Held

44.4K

View Full List

About CERUS CORP

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $250M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

More about CERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account